On December 28, 2019, just as news of the Wuhan plague sank its teeth into American society, Pfizer CEO Albert Bourla confronted then-FDA director Stephen Hahn with what he described as an intractable dilemma: Bourla lamented Pfizer’s “revenue loss,” a curious choice of words to describe a pharmaceutical manufacturer that netted $16.7 billion in 2019, the CEO of which earned $17mn in 2019 and $22mn in 2020–after the company’s Covid-19 vaccine h it the shelves. Those figures exclude the tens of millions of dollars Bourla gets from benefits, per diems and stock options, assets which, if added to his yearly salary, place him among the highest paid CEOs in the world.
Hahn, Bourla, and a gaggle of FDA and Pfizer officials held private talks to discuss Pfizer’s self-perceived financial woes. The meeting did not take place at Pfizer’s corporate headquarters in Manhattan. Nor did the conference happen at the FDA’s mammoth complex in Silver Springs, Maryland. This was unusual because official talks between the FDA and big pharma typically occur at one of those two locations, not a boardroom suite at the Hay-Adams Hotel in Washington, D.C.
Bourla had requested a clandestine gathering, having told Hahn that trade secrets would be analyzed and that Pfizer’s codified agreement with the FDA stipulated that Pfizer had authority to request covert discussions to prevent public dissemination of confidential information. The FDA’s acceptance of those terms shows that it and big pharma share a matrimonial bedchamber……Pfizer, the FDA, and Bribes Aplenty — Real Raw News